Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: A parallel group, triple blind, placebo-controlled study

American Journal of Gastroenterology

Volumn 97, Issue 11, 2002, Pages 2744-2749

  Cremonini, Filippo ^a,b   Di Caro, Simona ^a   Covino, Marcello ^a   Armuzzi, Alessandro ^a   Gabrielli, Maurizio ^a   Santarelli, Luca ^a   Nista, Enrico C ^a   Cammarota, Giovanni ^a   Gasbarrini, Giovanni ^a   Gasbarrini, Antonio ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; PROBIOTIC AGENT; RABEPRAZOLE; TINIDAZOLE;

ADULT; ANOREXIA; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIARRHEA; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC PAIN; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE FLORA; LACTOBACILLUS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SACCHAROMYCES BOULARDII; SCORING SYSTEM; TASTE DISORDER; VOMITING;

HELICOBACTER PYLORI; LACTOBACILLUS; SACCHAROMYCES BOULARDII;

EID: 0036840803     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2002.07063.x     Document Type: Article

References (22)

1. Deltenre M, Ntounda R, Jonas C, et al. Eradication of Helicobacterpylori: Why does it fail? Ital J Gastroenterol Hepatol 1998;30(suppl 3):S326-8.
2. Fuller R. Probiotics in human medicine. Ann Med 1990;22:37-41.
3. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001;15:163-9.
4. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000;14:1625-9.
5. Malfertheiner P, Mégraud F, O'Morain C, et al. Current concepts in the management of Helicobacterpylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
6. Vanderhoof JA, Whitney DB, Antonson DL, et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999;135:564-8.
7. Szajewska H, Kotowska M, Mrukowicz JZ, et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001;138:361-5.
8. Gotz V, Romankiewicz JA, Moss J, et al. Prophylaxis against ampicillin-associated diarrhea with Lactobacillus preparation. Am J Hosp Pharm 1979;36:754-7.
9. Surawicz MC, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study. Gastroenterol 1989;96:981-8.
10. Mc Farland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439-48.
11. De Boer WA, Thys JC, Borody TJ, et al. Proposal for use of a standard side effect scoring system studies exploring Helicobacter pylori treatement regimens. Eur J Gastroenterol Hepatol 1996;8:641-3.
12. Cremonini F, Di Caro S, Bartolozzi F, et al. The impact of probiotics in antibiotic-associated diarrhea: A meta-analysis of placebo-controlled trials. Gastroenterology 2001;120:A215.
13. Lewis SJ, Freedman AR. Review article: The use of biotherapeuthic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998;12:807-22.
14. Isolauri E, Sutas Y, Kankaanpaa P, et al. Probiotics effects on immunity. Am J Clin Nutr 2001;73(suppl 2):S444-50.
15. Erickson KL, Hubbard NE. Probiotic immunomodulation in health and disease. J Nutr 2000;130(suppl 2):S403-9.
16. Shanahan F. Probiotics in inflamatory bowel disease. Gut 2001;48:609.
17. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier fuction. Gastroenterology 2001;121:580-91.
18. Gasbarrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:79-83.
19. Buhling A, Radun D, Muller WA, et al. Influence of anti-Helicobacter pylori triple-therapy with metronidazole, omeprazole, clarithromycin on intestinal microflora. Aliment Pharmacol Ther 2001;15:1445-52.
20. Berg R, Bernasconi P, Fowler D, et al. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis 1993 Nov;168:1314-8.
21. Saxelin M, Pessi T, Salminen S. Fecal recovery following oral administration of Lactobacillus strain GG (ATCC 53103) in gelatine capsules to healthy volunteers. Int J Food Microbiol 1995;25:199-203.
22. Elmer GW, McFarland LV, Surawicz CM, et al. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999;13:1663-8.